stella
beta
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases — Stella
Recruiting
Back to Neurodegenerative Diseases trials
Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations
(1 site)
United States
Vanderbilt University Medical Center, Nashville, Tennessee
View full record on ClinicalTrials.gov